Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C. Smith, Neil P. Shah, Qi Wang et al.|Nature|2012Cited by 745
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Jennifer A. Kanakry et al.|Blood|2015Cited by 299
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid LeukemiaYi‐Bin Chen, Robert J. Soiffer, Mark J. Levis et al.|Biology of Blood and Marrow Transplantation|2014Cited by 234
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R. McCurdy, Leo Luznik, Yvette L. Kasamon et al.|Haematologica|2016Cited by 187
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AMLAmy Sexauer, Mark J. Levis|Blood|2012Cited by 172